Transparency in biomedical research: About the risks associated with the use of Avandia;Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia

Revista Medica de Chile

Volumn 138, Issue 9, 2010, Pages 1197-1200

  Salas, Sofía P ^a   Russo, Moisés ^a,b  

^a UNIVERSIDAD DIEGO PORTALES   (Chile)

^b Asesor del Comite de Etica en Investigacion Cientifica del Area Metropolitana Occidente   (Chile)

Author keywords

Biomedical research; Conflicts of interest; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ROSIGLITAZONE;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHILE; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; HUMAN; MEDICAL RESEARCH; PERSONNEL; REVIEW; RISK FACTOR;

BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; CHILE; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS; HYPOGLYCEMIC AGENTS; RESEARCH PERSONNEL; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 78649696467     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Rosiglitazone no longer recommended. The Lancet 2008; 372: 1520.
2. Graham DJ, Ouellet-Hellstrom R, Macurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone. JAMA 2010; 304:(doi:10.1001/jama.2010.920).
3. Juurlink DN. Rosiglitazone and the Case for Safety Over Certainty. JAMA 2010; 304:doi:10.1001/jama.2010.954).
4. Norris SL, Carson S. Drug class review: Thiazolidinediones. 2008. Publicado por Oregon Health and Science University. Disponible en http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. [Revisado el 30 mayo 2010].
5. Harris G, Research Ties Diabetes Drug to Heart Woes. Publicado el 19 de febrero 2010 en The New York Times. Disponible en http://www.nytimes.com/2010/02/20/health/policy/20avandia.html. [Revisado el 30 de mayo 2010].
6. Harris G, Caustic Government Report Deals Blow to Diabetes Drug. Publicado el 9 de julio 2010 en The New York Times. Disponible en http://www.nytimes.com/2010/07/10/health/10diabetes.html?_r=2&ref=health. [Revisado el 10 de julio 2010]
7. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
8. Nissen SE. Setting the RECORD Straight. JAMA 2010; 303: 1194-5.
9. DeAngelis CD, Fontanarosa PB. Ensuring integrity in industry-sponsored research: primum non nocere, revisited. JAMA 2010; 303: 1196-8.
10. Grassley C. Grassley Continues Case for Greater Independence in FDA's Post-market Review of Drugs. The United States Senate Committee on Finance. Publicado el 28 abril 2010. Disponible en http://finance.senate.gov/newsroom/ranking/release/?id=95a2f066-260f-49b3-8c0a-71e1efd790dc. [Revisado el 30 de mayo 2010].
11. Salas SP. [Recommendations of the Association of American Medical Colleges on industry support of medical education]. Rev Med Chile 2008; 136: 1085-6.
12. Romero W, Salas SP. [Disclosure of financial sources and conflicts of interest among research articles published in Revista Medica de Chile]. Rev Med Chile 2007; 135: 473-9.
13. Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824-31.
14. Orrico KB, Lin JK, Wei A, Yue H. Clinical consequences of disseminating the rosiglitazone FDA safety warning. Am J Manag Care 2010; 16: e111-6.
15. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009; 301: 1367-72.
16. Organización de las Naciones Unidas para la Educación, la Ciencia, y la Cultura. Creación de Comités de Bioética, Guía N° 1 2005. Disponible en http://www.unesco.org.uy/shs/es/areas-de-trabajo/ciencias-sociales/bioetica/documentos-publicaciones-en-bioetica.html. [Revisado el 7 de junio 2010].
17. Ministerio de Salud de Chile, Subsecretaría de Salud Pública. Ley 20.120 Sobre la investigación científica en el ser humano, su genoma, y prohíbe la clonación humana. 2006. Disponible en http://www.leychile.cl/Navegar?idNorma=253478&r=1. [Revisado el 7 de junio 2010].